Main Article Content

Lena Cerruti
Denis Lebel
Thierry Van Hees
Olivier Bourdon
Pascal Bonnabry
Anne Spinewine
Jean-Daniel Hecq
Jean-Francois Bussieres


Adverse drug reactions, adverse drug reaction reporting, pharmacovigilance, hospital pharmacy resident, perception



Pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse drug reactions (ADRs). Although pharmacovigilance is a responsibility for all healthcare professionals, this activity is an important part of a pharmacist’s practice. Hospital pharmacy residents are expected to have the necessary skills to monitor, manage, report and prevent ADRs as a part of their academic curriculum. Assessing and comparing perceptions of pharmacovigilance of hospital pharmacy residents from four different countries can contribute to a reflection about their education and their role in pharmacovigilance.


To assess and compare the perception of pharmacovigilance of hospital pharmacy residents from Belgium, France, Canada and Switzerland.


A cross-sectional study was conducted in March 2014 using an online -questionnaire administrated to 229 hospital pharmacy residents. Nineteen questions were organized into five sections: demographic data, pharmacovigilance education and practice, attitudes toward reporting adverse drug reactions, obstacles to reporting ADRs and measures to improve ADRs reporting rate.


Unlike the French residents, most of the other respondents believed that they had received an adequate pharmacovigilance education. The main obstacles to ADR reporting were similar: lack of experience and concern about overwork. The same measures concerning the development of pharmacovigilance were identified. Hospital residents expected local measures for a closer pharmacovigilance.


These observations lead us to think that standardizing and changing hospital pharmacy residents’ education and good practices in clinical pharmacovigilance are required to optimize patient care.

Abstract 99 | PDF Downloads 58


1. World Health Organization. The safety of medicines in public health programmes: Pharmacovigilance an essential tool . http://www.who.int/medicines/areas/quality_saf ety/safety_efficacy/Pharmacovigilance_B.pdf (October 21, 2014 ).
2. Van Grootheest K, Olsson Sten, Couper M, et al. Pharmacist’s role in reporting adverse drug reaction in international perspective. Pharmacoepidemi ol Drug Saf 2004;13:457- 64.
3. Vallano A, Cereza G, Pedros C, et al. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol 2005;60(6):653.
4. Nichols V, Thériault -Dubé I, Touzin J, et al. Risk Perception and Reasons for Noncompliance in Pharmacovigilance: a Qualitative Study Conducted in Canada. Drug Saf 2009;32(7):579- 90.
5. Elkalmi RM, Hassali MA, Ibrahim MI, Widodo RT, Efan QM, Hadi MA. Pharmacy Students’ Knowledge and Perceptions About Pharmacovigilance in Malaysian Public Universities. Am J Pharm Educ 2011 Jun 10;75(5):96.
6. Gavaza P, Bihn B. Pharmacy Students’ Attitudes Toward Reporting Serious Adverse Drug Events. Am J Pharm Educ 2012;76(10):194.
7. Kalari S, Dormarunno M, Zvenigorodsky O , Mohan A. Pharmacy Student Perceptions of Adverse Event Reporting. Am J Pharm Educ 2011;75(7):131.
8. Sharma S, Sharma J, Aggarwal T. A survey on knowledge and perception of pharmacy students towards adverse drug reaction (ADR) reporting. Asian Journal of Pharmaceutical and Clinical Research 2012;5(3):129- 31.
9. Federal agency for medicines and health products. Belgi an Centre for Pharmacovigilance. http://www.fagg - afmps.be/en/human_use/medicines/medicines/p harmacovigilance/bcph/ (September 10, 2014) .
10. Agence nationale de sécurité du médicament et des produits de santé. Organisation de la pharmacovigilance nationale . http://ansm.sante.fr/Declarer -un-effet - indesirable/Pharmacovigilance/Organisation -de- la-pharmacovigilance -nationale /(offset)/0 (September 10, 2014 ).
11. Swiss Agency for Therapeutic Products. Pharmacovigilance . https://www.swissmedic.ch/marktueberwachung /00135/00160/index.html?lang=e n (September 10, 2014 ).
12. Health Canada. Canada Vigilance Program . http://www.hc -sc.gc.ca/dhp - mps/medeff/vigilance -eng.php (September 10, 2014 ).
13. Bussières JF, Blond M , Lebel D. I nté gration de la pharmacovigilance à la pratique clinique. Journal de Pharm acie Cli nique 2006;25(2):1- 8.
14. The Uppsala monitoring centre, World Health Organization. Vigibase . http://www.who - umc.org/DynPage.aspx?id=98082&mn1=7347& mn2=7252&mn3=7322&mn4=7326 (October 15, 2014 ).
15. Smith MP, Webley SD. Pharmacovigilance teaching in UK undergraduate pharmacy programmes. Pharmacoepidemiol Drug Saf 2013;22(3):223- 8.
16. Académie nationale de médecine française. Montastruc JL, Tillement JP. Pharmacovigilance: actualités et perspectives. (November 20, 2012) . http://www .academie - medecine.fr/wp - content/uploads/2013/07/pharmacovigilanceVE RSION -11.pdf (September 18, 2014 ).
17. Sullivan KM, Spooner LM. Adverse -drug - reaction reporting by pharmacy students in a teaching hospital. Am J Health -Syst Pharm 2008;65(12):1177- 9. 18.
18. Baniasadi S, Habibi M, Haghgoo R, et al. Increasing the Number of Adverse Drug Reactions Reporting: the Role of Clinical Pharmacy Residents. Iran J Pharm Res 2014;13(1):291- 7.

Most read articles by the same author(s)